Clinical trials: Sirolimus, completed
Adult Solid Neoplasm
Tivantinib and Temsirolimus in Treating Patients With Solid Tumors That is Metastatic or Cannot be Removed by Surgery
This phase I trial studies the side effects and best dose of tivantinib when given in combination with temsirolimus in treating patients with solid tumors that have spread to other parts of the body or cannot be removed by…
- Trial name
- NCT01625156
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Temsirolimus
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- National Cancer Institute (NCI)
Renal Function
Evaluation of Early Conversion to Everolimus From Cyclosporine in de Novo Renal Transplant Recipients
This study is designed to evaluate if early conversion to everolimus from cyclosporine in de novo renal transplant recipients can improve long-term renal function and slow down the progression of chronic allograft nephropathy
- Trial name
- NCT00634920
- Testing
- everolimus, cyclosporine A, Enteric Coated Mycophenolate Sodium (EC-MPS)
- Where
- 8 sites in Denmark, Norway and 1 more
- Volunteers
- 204 people
- Sponsor
- Novartis Pharmaceuticals
Coronary Heart Disease
Recovery of Left Ventricular Function in Chronic Total Occluded Coronary Arteries
The study is a randomised comparison of recanalisation of chronic occluded coronary arteries with implantation of Sirolimus eluting stents and medical therapy.
- Trial name
- REVASC (NCT01924962)
- Testing
- revascularisation
- Where
- Germany
- Volunteers
- 205 people
- Sponsor
- University Heart Center Freiburg - Bad Krozingen
Stable Angina, Unstable Angina
Optical Coherence Tomography Comparison of Neointimal Coverage Between CRE8 DES and BMS
The purpose of the study is to demonstrate the non-inferiority of Cre8 (CID) Drug Eluting Stent, studied 3 months after implant, compared to Vision/Multilink8 Bare Metal Stent (Abbott) studied at 1 month, in terms of neointimal…
- Conditions
- Stable Angina, Unstable Angina, NSTEMI
- Trial name
- DEMONSTRATE (NCT01543373)
- Testing
- Amphilimus Eluting Stent, Bare Metal Stent
- Where
- 6 sites in Italy, Netherlands
- Volunteers
- 38 people
- Sponsor
- CID - Carbostent & Implantable Devices
Malignant PEComa
A Phase 2 Study of Nab-sirolimus (ABI-009) in Patients With Advanced Malignant PEComa
A phase 2 multi-center investigation of efficacy of nab-sirolimus (formerly known as ABI-009 or nab-rapamycin) in patients with advanced malignant perivascular epithelioid cell tumor (PEComa).
- Trial name
- AMPECT (NCT02494570)
- Testing
- nab-Sirolimus
- Where
- 9 sites in United States
- Volunteers
- 34 people
- Sponsor
- Aadi Bioscience, Inc.
Metastatic Breast Cancer
PhIb BKM120 or BEZ235+Endocrine Treatment in Post-Menopausal Patients With Hormone Receptor + Metastatic Breast Cancer
This is an open-label phase Ib multi-institution trial that evaluates the safety profile/tolerability and preliminary anti-tumor effect of BKM120 (a PI3K inhibitor) and endocrine therapy combination and BEZ235 (a PI3K/ mTOR…
- Trial name
- NCT01248494
- Testing
- BEZ235, BKM 120, Letrozole
- Where
- 6 sites in United States
- Volunteers
- 72 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Uveitis, Intermediate Uveitis
Sirolimus as Therapeutic Approach to Uveitis
The purpose of this study is to find out about the safety and effectiveness of the study drug, sirolimus, in patients with uveitis and to utilize the potential effectiveness of sirolimus, and yet to avoid the potential…
- Conditions
- Uveitis, Intermediate Uveitis, Posterior Uveitis, Panuveitis
- Trial name
- SAVE (NCT00908466)
- Testing
- Sirolimus (rapamycin)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Johns Hopkins University
Gastrointestinal Stromal Tumors
Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors
This trial was a Phase I/II, non-randomized, open label, multi-center study, following a sequential 2-part design.
- Trial name
- NCT01275222
- Testing
- RAD001, Imatinib 600mg/day (Glevec is the brand name for imatinib), Imatinib 800mg/day (Glevec is the brand name for imatinib)
- Where
- 16 sites in United States, Belgium and 2 more
- Volunteers
- 117 people
- Sponsor
- Novartis Pharmaceuticals
Coronary Artery Disease, Diabetes
Clinical Trial of Abluminus DES+ Sirolimus Eluting Stent Versus Everolimus-eluting DES
The objective of the study is to compare angiographic and clinical performance of Abluminus DES+ versus Everolimus-eluting DES in patients with diabetes mellitus.
- Trial name
- NCT03399994
- Testing
- device implantation during coronary angioplasty
- Where
- 6 sites in Italy
- Volunteers
- 137 people
- Sponsor
- Fondazione Evidence per Attività e Ricerche Cardiovascolari ONLUS
Liver Transplantation
Tumor Characteristics, Pre-transplant Treatments and Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma
Recurrence after liver transplantation for hepatocellular carcinoma (HCC) represents an important cause of mortality for this surgical population.
- Trial name
- NCT02995096
- Testing
- Pre-treatment, Sirolimus based immunosuppression
- Volunteers
- 23,124 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Graft Versus Host Disease, GVHD
Tacrolimus and Sirolimus as Prophylaxis After Allogenic Non-myeloablative Peripheral Blood Stem Cell Transplantation
The purpose of this study is to extend the use of Tacrolimus and Sirolimus to determine how effective it is in preventing graft versus host disease (GVHD)in patients that have received non-myeloablative peripheral blood stem cell…
- Trial name
- NCT00282282
- Testing
- tacrolimus, sirolimus, fludarabine
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Dana-Farber Cancer Institute
Graft-versus-Host Disease
Single-centre Study of Everolimus as GvHD Prophylaxis After Post-Transplantation Cyclophosphamide After Allogeneic SCT
A phase II clinical study to assess the efficacy of short-term everolimus as prophylaxis for Graft-versus-Host disease (GvHD) in addition to post-transplantation cyclophosphamide after allogeneic hematopoietic stem cell…
- Trial name
- OCTET-Ever (NCT02812940)
- Testing
- Everolimus
- Where
- Germany
- Volunteers
- 19 people
- Sponsor
- University of Cologne
Graft Rejection
Safety/Efficacy of Everolimus and Neoral® in Adult Cardiac Transplant Patients With Established Allograft Vasculopathy
Everolimus is an immunosuppressive drug that is being studied for preventing acute rejection that can happen after heart transplantation. It is usually used in combination with other immunosuppressive drugs such as cyclosporine.
- Trial name
- NCT00097968
- Testing
- everolimus
- Where
- 6 sites in United States
- Sponsor
- Novartis Pharmaceuticals
Liver Transplantation
REnal Function in Liver Transplantation: Everolimus With Calcineurin Inhibitor (CNI)-Sparing sTrategy
The purpose of this study was, starting from the Italian clinical practice in liver transplantation, to optimize the immunosuppressive therapy, considering specific patient characteristics as alcoholic cirrhosis, hepatitis C…
- Trial name
- REFLECT (NCT02115113)
- Testing
- Everolimus, Tacrolimus
- Where
- 14 sites in Italy
- Volunteers
- 78 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Breast Cancer
Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer
This randomized, double blind, placebo controlled trial will evaluate the impact of adding everolimus to the combination of weekly paclitaxel plus bevacizumab in the first-line treatment of women with HER2-negative metastatic…
- Trial name
- NCT00915603
- Testing
- Everolimus, Bevacizumab, Paclitaxel
- Where
- 15 sites in United States
- Volunteers
- 113 people
- Sponsor
- SCRI Development Innovations, LLC
Hormone-Resistant Prostate Cancer, Prostate Adenocarcinoma
Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer
This phase I/II trial is studying the side effects of giving cixutumumab together with temsirolimus and to see how well it works in treating patients with metastatic prostate cancer.
- Conditions
- Hormone-Resistant Prostate Cancer, Prostate Adenocarcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
- Trial name
- NCT01026623
- Testing
- Cixutumumab, Diagnostic Laboratory Biomarker Analysis, Temsirolimus
- Where
- 4 sites in United States
- Volunteers
- 16 people
- Sponsor
- National Cancer Institute (NCI)
Relapsed, Refractory Multiple Myeloma
RAPA-201 T Cell Therapy for Relapsed, Refractory Multiple Myeloma
RAPA-201-RRMM is an open-label, single-arm, non-randomized multicenter phase II study of RAPA-201 autologous T cells in adults with relapsed, refractory multiple myeloma who have received at least three (3) prior lines.
- Trial name
- NCT04176380
- Testing
- RAPA-201 Autologous T cells
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Rapa Therapeutics LLC
Coronary Artery Disease
Registry to Evaluate Efficacy of Xience/Promus Versus Cypher in Reducing Late Loss After Stenting
The objective of this study is to evaluate the safety and long-term effectiveness of coronary stenting with the everolimus-eluting stent (EES) and to determine clinical device and procedural success during commercial use of EES…
- Trial name
- NCT00960648
- Testing
- Xience/Promus, Cypher
- Where
- 18 sites in South Korea
- Volunteers
- 3,056 people
- Sponsor
- Seoul National University Hospital
Coronary Artery Disease
NEXUS Study for the Treatment of de Novo Native Coronary Artery Lesions
The objective of this study is to evaluate the effectiveness and safety of the CYPHER NxT Sirolimus-eluting Coronary Stent on the BX SONIC Over-the-Wire (OTW) Stent Delivery System (SDS) in patients with de novo native coronary…
- Trial name
- NCT00231283
- Testing
- CYPHER NxT SES ON BX SONIC OTW STENT DELIVERY SYSTEM (SDS)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Cordis US Corp.
Advanced Solid Tumors
Safety Study of Bevacizumab, Everolimus and LBH589 (BEL) for Advanced Solid Tumors
The main purpose of this study is to test the safety of three study drugs, bevacizumab (Avastin™), Everolimus (Afinitor™) and LBH589 (Panobinostat) when they are given together.
- Trial name
- BEL (NCT01055795)
- Testing
- Bevacizumab, Everolimus and LBH589
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Herbert Hurwitz
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.